Laboratory models made from human airway cells have been used to better understand primary ciliary dyskinesia (PCD) and to test potential treatments. This review examined published research on existing models and found that a range of different approaches have been used, including cultures of patient airway cells, organoids, spheroids and stem cell-derived airway cells. These models have been used to test potential treatments, and to study how infections, medications and environmental exposures affect the airways. However, the methods used to create and test these models varied considerably between studies, making it more difficult to compare results. The review highlights the need for agreed standards on how PCD models should be tested and reported. This will improve research quality and help accelerate the development and testing of new treatments for people living with PCD. Published in July 2026.

This review discusses the requirements of laboratory models specifically used to develop and test new treatments for primary ciliary dyskinesia (PCD). These models, which can be made from patient airway cells or stem cell-based systems, are designed to closely mimic the disease. The review highlights the challenges of designing reliable models for testing potential treatments and bringing through promising treatments from the laboratory to the clinic. The tools used to assess whether these treatments are effective are also discussed, including the correction of the genetic code, and restoration of cilia structure and movement. Finally, the review highlights the importance of developing shared research standards and consistent reporting guidelines to improve the quality and comparability of studies. This will help to accelerate the development of safe and effective treatments for people living with PCD. Published in July 2026.

This systematic review reports on growth and nutrition-related outcomes in people with primary ciliary dyskinesia (PCD) and highlights the need for their timely and frequent assessment as standards of care. Published in April 2026. Summary available in English - French - German - Spanish - Italian

Healthcare professionals from 35 countries reported that people with Primary Ciliary Dyskinesia (PCD) often face delays in diagnosis and challenges accessing specialist care because the condition is not well known, services are limited, and funding is insufficient. They agreed that improving awareness of PCD, strengthening collaboration between healthcare centres, and expanding access to expert diagnostic and care services are key steps to improving outcomes for patients worldwide. Published in March 2026. Summary available in English

Please find here a lay summary for the article “Patients’ research priorities and participation in primary ciliary dyskinesia research” authored by Yin Ting Lam, Laura Behan, Katie Dexter, Lucy Dixon, Claudia E. Kuehni, Leonie Schreck, Jane Lucas & Myrona Goutaki. Available in many versions: English - French - Spanish - German - Turkish - Italian

Lay summary of the 4 days of conference can be found here

The PCD track at the World Bronchiectasis Conference 2026, held in Hannover (Germany) on 25 June, brought together experts from around the world to share the latest advances in PCD diagnosis, management and research. Find the conference summary here and catch up on the key presentations, discussions and future research directions. A special thank you to Erin Cant (University of Dundee) for attending the conference in person and preparing this summary (available in English).

In honor of PCD Awareness Month, and with the invaluable support of patient representatives whom we sincerely thank, we are pleased to share a lay summary of the BEAT-PCD projects and its key achievements. This summary provides an overview of the presentation by Myrona Goutaki, detailing the progress of the different projects and updates for each work package within the BEAT-PCD network. We hope this offers a clear insight into the ongoing efforts and advancements in the field of Primary Ciliary Dyskinesia. Available in translated versions: English - French - Spanish